Skip to content
TrialScanner

NCT04412018

An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19

Phase 2CompletedAMRNCollaborator

Registry record

Lead sponsor
Canadian Medical and Surgical Knowledge Translation Research Group
Conditions
COVID-19; Inflammatory Response
Primary completion
Nov 6, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04412018 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04412018: An Investigation on the... | TrialScanner